Scott Gottlieb Quotes


Patients would be better off if states were able to tailor the benefits that Medicaid covers - targeting resources to sicker people and giving healthy adults cheaper, basic coverage.


Citations

Gottlieb, Scott. "To Fix Medicaid, Give States Real Flexibility." Forbes, 2017.

Related Quotes

This quotation is interesting for two reasons: First, President Donald Trump had campagned on teh promise of Universal Health Insurance and in the early days of the Tramp Administration, Trump's Manager of the Office of Management and Budget effectivly repudiated Trum's campaign promise. Second, it ilustrates the narrownss to the thinking of soem of the very conservative politicians of the era. Virtually every industiral democracy in the world had universial health or health insurance coverage. Mulvaney's thinking was limited to teh classic U. S. model of health insurance premiums being paid by individuals and companies to privat insurance companies. Yet most other countries had teh government coelect the money and pay the health providers (the single payer system) of simply funded universal ehalth care through the general tax revenues, and had no specific act of buying a policy so there was no way for people to refuse.


There were many countries whose laws proclaimed that health care was a right but could not deliver the health care to many of its citizens. However, every developed country except the United States considered health care a right and delivered health care to its people. The large majority of U. S. citizens received good health care but not as a right.


Scott Gottlieb
Scott Gottlieb
  • Born: June 11, 1972
  • Nationality: American
  • Profession: Public Servant

Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.